Turing Pharma seeks CEO to replace Shkreli, plans job cuts
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
NEW YORK] Turing Pharmaceuticals said on Tuesday it is seeking a new chief executive to replace Martin Shkreli, the price-gouging entrepreneur who is facing US charges of securities fraud, and will cut jobs in a restructuring.
The private Swiss-based company will also expand its board to include new, independent members, it added.
Shkreli, 32, resigned as CEO on Friday, a day after his arrest on charges that he had engaged in a Ponzi-like scheme. He pleaded not guilty and was released on US$5 million bail.
On Monday, KaloBios Pharmaceuticals said Shkreli was "terminated" as CEO and had resigned from the board.
Turing did not specify the number of job cuts in a statement. It could not be immediately reached for comment. "These staff changes put us in the best position to continue executing on our long-term plan," said Chairman and Interim Chief Executive Ron Tilles, who took over Shkreli's job on Friday.
Shkreli gained notoriety when, as Turing's CEO, he raised the price of a life saving drug overnight to US$750 from US$13.50.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
REUTERS
Share with us your feedback on BT's products and services
TRENDING NOW
Ministry of Home Affairs Permanent Secretary Pang Kin Keong to retire
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
